服脂肪肝:牛可以对抗MASLD中的代谢功能障碍吗?
Lin Meng1, Fayu Lu2, Bing Zhang3
1First Clinical College, China Medical University, Shenyang, Liaoning Province, 110122, China.
Cell communication and signaling : CCS
|October 15, 2025
概括
与脂肪性肝病 (MASLD) 相关的代谢功能障碍是一个日益严重的全球健康问题. 这篇评论强调了 taurine 的重要性.
科学领域:
- 肝病学和代谢研究.
背景情况:
- 与脂肪性肝病 (MASLD) 相关的代谢功能障碍是全球最常见的慢性肝病.
- MASLD涉及过度的肝脂积累,可能会发展为非酒精性脂肪肝炎 (NASH),纤维化和肝细胞癌 (HCC).
- 目前对MASLD分子机制的理解是不完整的,没有批准的药理疗法.
研究的目的:
- 为了探索MASLD的发病机制.
- 审查MASLD的早期诊断策略.
- 调查氨酸在减轻通过肠肝轴的MASLD进展方面的潜力.
主要方法:
- 这项研究是对现有文献的综述.
- 它综合了有关MASLD的当前研究.
- 它侧重于肠肝轴和 taurine 的作用.
主要成果:
- MASLD的病原机制需要进一步阐明.
- 早期诊断工具正在开发中.
- 氨酸在潜在地减少MASLD进展方面表现有前途.
结论:
- 氨酸可能是MASLD的新疗法策略.
- 对 taurine 作用的进一步研究可能会导致用于 MASLD 管理的新临床干预措施.
相关概念视频
Overview of Lipid Metabolism
4.8K
Lipid metabolism is a crucial process in the human body that involves the synthesis and degradation of lipids. This process is essential for energy production, cell membrane formation, and hormone production, among other functions.
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
Lipolysis: The Breakdown of Lipids:
Lipolysis is the process of breaking down lipids, particularly triglycerides, into glycerol and fatty acids. This process typically occurs in the adipose tissue and is triggered by various hormones, including glucagon and...
4.8K
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
180
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
180
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
211
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
211
Overview of Carbohydrate Metabolism
3.2K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
3.2K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion
165
Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
165
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
249
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
249


